First-Generation Cell and Gene Therapy Blockbusters: Zolgensma and Yescarta

Published on Alliance for Regenerative Medicine (LinkedIn)

Two landmark therapies, Zolgensma and Yescarta, highlight how cell and gene therapies can rapidly scale into blockbuster success. Both treatments, approved within the past few years, have already reached global patients and surpassed billion-dollar sales. Their journeys underscore three common factors: global reach, high unmet need with strong efficacy, and early access strategies.

👉 Read the full article: First-Generation Success Stories in CGT

Disclaimer

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.